{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:17:24Z","timestamp":1795216644804,"version":"4.10.3"},"reference-count":38,"publisher":"Association of Basic Medical Sciences of FBIH","issue":"4","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomol Biomed"],"abstract":"<jats:p>Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory autoimmune disease in childhood, significantly contributing to both short- and long-term disability. While certain human leukocyte antigen (HLA) class II alleles are known to be associated with specific subgroups of JIA, emerging evidence suggests a strong correlation between these alleles and treatment response. This study involved 143 JIA patients diagnosed according to International League of Associations for Rheumatology criteria. Each patient underwent HLA class II typing, including HLA-B27, as well as tests for rheumatoid factor (RF) and antinuclear antibodies (ANA). Comprehensive rheumatological assessments were conducted at diagnosis, with follow-ups at three and six months post-onset. After six months of methotrexate (MTX) treatment, patients were categorized as responders or non-responders. Responders achieved clinically inactive disease based on the American College of Rheumatology Provisional Criteria for Defining Clinical Inactive Disease and Clinical Remission. Non-responders, who did not reach clinically inactive disease after six months of treatment, required the addition of another non-biological disease-modifying antirheumatic drug (DMARD) or a biological DMARD. Our analysis revealed that the HLA-DRB1*01 allele is a significant prognostic marker for therapeutic response, predicting therapeutic resistance (P=0.01). The most prevalent HLA-DRB1 alleles in the treatment-resistant group were HLA-DRB1*08:11 (11.3%), HLA-DRB1*01:01 (8.5%), HLA-DRB1*01:13, HLA-DRB1*04:11 (7%), HLA-DRB1*08:13, and HLA-DRB1*08:15 (4.2%). These findings highlight the critical role of HLA class II alleles in pediatric rheumatology, particularly in relation to treatment response and disease prognosis. In the era of personalized medicine, understanding the genetic contributions to treatment response and outcomes in JIA patients is essential. A key limitation of this study was the lack of comparison of treatment responses across different JIA subtypes. Future studies should prioritize evaluating MTX efficacy within specific JIA subgroups to enable a more tailored understanding of its effectiveness.<\/jats:p>","DOI":"10.17305\/bb.2024.11043","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T14:42:14Z","timestamp":1730385734000},"page":"883-893","source":"Crossref","is-referenced-by-count":0,"title":["HLA-DRB1*01 predicts treatment outcome in juvenile idiopathic arthritis: A retrospective-prospective cohort study"],"prefix":"10.17305","volume":"25","author":[{"given":"Adisa","family":"\u010cengi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snije\u017eana","family":"Hasanbegovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1617-8305","authenticated-orcid":false,"given":"Izeta","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Sulji\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velma","family":"Selmanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"\u0110ozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elma","family":"Fejzi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamija","family":"Ze\u010devi\u0107-Pa\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nejra","family":"D\u017eananovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6922","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"177718","doi-asserted-by":"crossref","unstructured":"Chen B, Li J, He C, Li D, Tong W, Zou Y, et al. Fifer: tackling underutilization in the serverless era. Mol Med Rep. 2020;15:1943-51. doi:10.3892\/mmr.2017.6248","DOI":"10.3892\/mmr.2017.6248"},{"key":"177719","doi-asserted-by":"crossref","unstructured":"Hou X, Qu H, Zhang S, Qi X, Hakonarson H, Xia Q, et al. The multi-omics architecture of juvenile idiopathic arthritis. Cells. 2020;9:2301. doi:10.3390\/cells9102301","DOI":"10.3390\/cells9102301"},{"key":"177720","doi-asserted-by":"crossref","unstructured":"De Silvestri A, Capittini C, Poddighe D, Marseglia GL, Mascaretti L, Bevilacqua E, et al. HLA-DRB1 alleles and juvenile idiopathic arthritis: diagnostic clues emerging from a meta-analysis. Autoimmun Rev. 2017;16:1230-6. doi:10.1016\/j.autrev.2017.10.007","DOI":"10.1016\/j.autrev.2017.10.007"},{"key":"177721","doi-asserted-by":"crossref","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O\u2019Neil KM, Zeft AS, et al. Trail of early aggressive therapy in polyarticular juvenile idiopathic arthiritis. Arthritis Rheum. 2012;64:2012-21. doi:10.1002\/art.34343","DOI":"10.1002\/art.34343"},{"key":"177722","doi-asserted-by":"crossref","unstructured":"Stanevicha V, Eglite J, Zavadska D, Sochnevs A, Lazareva A, Guseinova D, et al. HLA B27 allele types in homogeneous groups of juvenile idiopathic arthritis patients in latvia. Pediatr Rheumatol Online J. 2010;8:26. doi:10.1186\/1546-0096-8-26","DOI":"10.1186\/1546-0096-8-26"},{"key":"177723","doi-asserted-by":"crossref","unstructured":"\u017cuber Z, Turowska-Heydel D, Sobczyk M, Chudek J. Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis. Reumatologia. 2015;53:125-30. doi:10.5114\/reum.2015.53133","DOI":"10.5114\/reum.2015.53133"},{"key":"177724","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology (2004) international league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-2. doi:10.3899\/jrheum.031235"},{"key":"177725","doi-asserted-by":"crossref","unstructured":"Barut K, Adrovic A, Sahin S, Tarcin G, Tahaoglu G, Koker O, et al. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: a single-center experience. Int J Rheum Dis. 2019;22:1661-9. doi:10.1111\/1756-185X.13649","DOI":"10.1111\/1756-185X.13649"},{"key":"177726","doi-asserted-by":"crossref","unstructured":"Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. Childhood arthritis rheumatology research alliance. Arthritis Care Res. 2011;63:929-36. doi:10.1002\/acr.20497","DOI":"10.1002\/acr.20497"},{"key":"177727","doi-asserted-by":"crossref","unstructured":"Bridges JM, Mellins ED, Cron RQ. Recent progress in the treatment of non-systemic juvenile idiopathic arthritis. Fac Rev. 2021;10:23. doi:10.12703\/r\/10-23","DOI":"10.12703\/r\/10-23"},{"key":"177728","doi-asserted-by":"crossref","unstructured":"Glerup M, Herlin T, Twilt M. Remission rate is not dependent on the presence of systemic juvenile idiopathic arthritis. Fac. 2017;36:671-6. doi:10.1007\/s10067-017-3540-x","DOI":"10.1007\/s10067-017-3540-x"},{"key":"177729","doi-asserted-by":"crossref","unstructured":"Litwin CM, Binder SR. ANA testing in the presence of acute and chronic infections. J Immunoassay Immunochem. 2016;37:439-52. doi:10.1080\/15321819.2016.1174136","DOI":"10.1080\/15321819.2016.1174136"},{"key":"177730","doi-asserted-by":"crossref","unstructured":"Murray KJ, Moroldo MB, Donnelly P, Prahalad S, Passo MH, Giannini EH, et al. Age-specific effects of juvenile rheumatoid arthritis-associated HLA alleles. Arthritis Rheum. 1999;42:1843-53. doi:10.1002\/1529-0131(199909)42:9&#x2329;1843::AIDANR8&#x232A;3.0.CO;2-M","DOI":"10.1002\/1529-0131(199909)42:9<1843::AID-ANR8>3.0.CO;2-M"},{"key":"177731","doi-asserted-by":"crossref","unstructured":"Thomson W, Barrett JH, Donn R, Pepper L, Kennedy LJ, Ollier WER, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatol Oxf Engl. 2002;41:1183-9. doi:10.1093\/rheumatology\/41.10.1183","DOI":"10.1093\/rheumatology\/41.10.1183"},{"key":"177732","unstructured":"Turowski G, Pietrzyk JJ. HLA gene and haplotype frequencies in the population of southern Poland. Arch Immunol Ther Exp (Warsz). 1979;27:591-600."},{"key":"177733","doi-asserted-by":"crossref","unstructured":"Taurog JD. The mystery of HLA-B27:if it isn\u2019t one thing, it\u2019s another. Arthritis Rheum. 2007;56:2478-81. doi:10.1002\/art.22807","DOI":"10.1002\/art.22807"},{"key":"177734","doi-asserted-by":"crossref","unstructured":"Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, et al. Time of disease-modifing antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug-free remission in young adulthood. Arthritis Care Res. 2019;71:471-81. doi:10.1002\/acr.23709","DOI":"10.1002\/acr.23709"},{"key":"177735","doi-asserted-by":"crossref","unstructured":"Shoop-Worrall SJW, Wu Q, Davies R, Hyrich KL, Wedderburn LR. Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence. Lancet Child Adolesc Health. 2019;3:725-33. doi:10.1016\/S2352-4642(19)30188-9","DOI":"10.1016\/S2352-4642(19)30188-9"},{"key":"177736","doi-asserted-by":"crossref","unstructured":"Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the food and drug administration. Arthritis Rheum. 2010;62:2517-24. doi:10.1002\/art.27511","DOI":"10.1002\/art.27511"},{"key":"177737","doi-asserted-by":"crossref","unstructured":"De Inocencio J, Giannini EH, Glass DN. Can genetic markers contribute to the classification of juvenile rheumatoid arthritis?. J Rheumatol Suppl. 1993;40:12-18. doi:10.1136\/adc.77.6.530","DOI":"10.1136\/adc.77.6.530"},{"key":"177738","doi-asserted-by":"crossref","unstructured":"Yanagimachi M, Miyamae T, Naruto T, Hara T, Kikuchi M, Hara R, et al. Association of HLA-A*02:06 and HLA-DRB1*04:05 with clinical subtypes of juvenile idiopathic arthritis. J Hum Genet. 2010;56:196-9. doi:10.1038\/jhg.2010.159","DOI":"10.1038\/jhg.2010.159"},{"key":"177739","doi-asserted-by":"crossref","unstructured":"Smerdel A, Ploski R, Flat\u00f8 B, Musiej-Nowakowska E, Thorsby E, F\u00f8rre \u00d8. Juvenile idiopathic arthritis (JIA) is primarily associated with HLA-DR8 but not DQ4 on the DR8-DQ4 haplotype. Ann Rheum Dis. 2002;61:354-7. doi:10.1136\/ard.61.4.354","DOI":"10.1136\/ard.61.4.354"},{"key":"177740","doi-asserted-by":"crossref","unstructured":"Haasnoot AM, Schilham MW, Kamphuis S, Hissink Muller PC, Heiligenhaus A, Foell D, et al. Identification of an amino acid motif in HLA\u2013DR\u03b21 that distinguishes uveitis in patients with juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70(7):1155-65. doi:10.1002\/art.40484","DOI":"10.1101\/140954"},{"key":"177741","doi-asserted-by":"crossref","unstructured":"Ali AA, Khalid KE, Mohammed SE, Akhtar MS, Saeed OK. Association of human leukocyte antigen (HLA) class II (DRB1 and DQB1) alleles and haplotypes with rheumatoid arthritis in sudanese patients. Front Immunol. 2023;14:1178546. doi:10.3389\/fimmu.2023.1178546","DOI":"10.3389\/fimmu.2023.1178546"},{"key":"177742","doi-asserted-by":"crossref","unstructured":"Inoue M, Nagafuchi Y, Ota M, Tsuchiya H, Tateishi S, Kanda H, et al. Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis. Sci Rep. 2023;13:15250. doi:10.1038\/s41598-023-42324-6","DOI":"10.1038\/s41598-023-42324-6"},{"key":"177743","doi-asserted-by":"crossref","unstructured":"Hollenbach JA, Thompson SD, Bugawan TL, Ryan M, Sudman M, Marion M, et al. Juvenile idiopathic arthritis and HLA class I and class II intercations and age-at-onset effects. Arthritis Rheum. 2010;62:1781-91. doi:10.1002\/art.27424","DOI":"10.1002\/art.27424"},{"key":"177744","doi-asserted-by":"crossref","unstructured":"Wysocki T, Olesi\u0144ska M, Paradowska-Gorycka A. Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis-from research to clinical practice. Cells. 2020;9:1127. doi:10.3390\/cells9051127","DOI":"10.3390\/cells9051127"},{"key":"177745","doi-asserted-by":"crossref","unstructured":"La Bella S, Rinaldi M, Di Ludovico A, Di Donato G, Di Donato G, Salpietro V, et al. Genetic background and molecular mechanisms of juvenile idiopathic arthritis. Int J Mol Sci. 2023;24:1846. doi:10.3390\/ijms24031846","DOI":"10.3390\/ijms24031846"},{"key":"177746","doi-asserted-by":"crossref","unstructured":"Reviron D, Perdriger A, Toussirot E, Wendling D, Balandraud N, Guis S, et al. Influence of shared epitope\u2013negative HLA\u2013DRB1 alleles on genetic susceptibility to rheumatoid arthritis. Arthritis Rheum. 2001;44:535-40. doi:10.1002\/1529-0131(200103)44:3&#x2329;535::AIDANR101&#x232A;3.0.CO;2-Z","DOI":"10.1002\/1529-0131(200103)44:3<535::AID-ANR101>3.0.CO;2-Z"},{"key":"177747","doi-asserted-by":"crossref","unstructured":"Nagafuchi Y, Shoda H, Sumitomo S, Nakachi S, Kato R, Tsuchida Y, et al. Immunophenotyping of rheumatoid arthritis reveals a linkage between HLA-DRB1 genotype, CXCR4 expression on memory CD4+ T cells and disease activity. Sci Rep. 2016;6:29338. doi:10.1038\/srep29338","DOI":"10.1038\/srep29338"},{"key":"177748","doi-asserted-by":"crossref","unstructured":"Ling SF, Bluett J. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update. Pharmacogenomics. 2020;21:3-6. doi:10.2217\/pgs-2019-0154","DOI":"10.2217\/pgs-2019-0154"},{"key":"177749","doi-asserted-by":"crossref","unstructured":"Ben Tekaya A, Mokaddem S, Athimini S, Kamoun H, Mahmoud I, Abdelmoula L. Risk factors for rheumatoid arthritis-associated interstitial lung disease: a retrospective study. Multidiscip Respir Med. 2022;17:877. doi:10.4081\/mrm.2022.877","DOI":"10.4081\/mrm.2022.877"},{"key":"177750","doi-asserted-by":"crossref","unstructured":"Hersh AO, Prahalad S. Immunogenetics of juvenile idiopathic arthritis: a comprehensive review. J Autoimmun. 2015;64:113-24. doi:10.1016\/j.jaut.2015.08.002","DOI":"10.1016\/j.jaut.2015.08.002"},{"key":"177751","unstructured":"Ali AAI, Moatter T, Baig JA, Iqbal A, Hussain A, Iqbal MP. Polymorphism of HLA-DR and HLA-DQ in rheumatoid arthritis patients and clinical response to methotrexate\u2013a hospital-based study. J Pak Med Assoc. 2006;56:452-456."},{"key":"177752","doi-asserted-by":"crossref","unstructured":"O\u2019Dell JR, Nepom BS, Haire C, Gersuk VH, Gaur L, Moore GF, et al. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis. 1998;57:209-13. doi:10.1136\/ard.57.4.209","DOI":"10.1136\/ard.57.4.209"},{"key":"177753","doi-asserted-by":"crossref","unstructured":"Eng SWM, Duong TT, Rosenberg AM, Morris Q, Yeung SM. The biologic basis of clinical heterogeneity in juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:3463-75. doi:10.1002\/art.38875","DOI":"10.1002\/art.38875"},{"key":"177754","doi-asserted-by":"crossref","unstructured":"Ayuso VK, Makhotkina N, van Tent-Hoeve M, de Groot-Mijnes JD, Wulffraat NM, Rothova A, et al. Pathogenesis of juvenile idiopathic arthritis associated uveitis: the known and unknown. Surv Ophthalmol. 2014;59:517-31. doi:10.1016\/j.survophthal.2014.03.002","DOI":"10.1016\/j.survophthal.2014.03.002"},{"key":"177755","doi-asserted-by":"crossref","unstructured":"Beesley RP, Hyrich KL, Humphreys JH. doi:10.1093\/rheumatology\/kead700","DOI":"10.1093\/rheumatology\/kead700"}],"container-title":["Biomolecules and Biomedicine"],"original-title":[],"link":[{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/11043\/3633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/11043\/3633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:03:35Z","timestamp":1795215815000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/11043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,3,7]]}},"URL":"https:\/\/doi.org\/10.17305\/bb.2024.11043","relation":{},"ISSN":["2831-090X","2831-0896"],"issn-type":[{"value":"2831-090X","type":"electronic"},{"value":"2831-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}